Weekly Highlights: Executive Changes at Three Pharma Firms and Latest Hospital Payment Reforms

Chairman of Sinopharm Group Co., Ltd. Replaced

Recently, Sinopharm Group Co., Ltd. announced changes in the composition of its board committees, with Zhao Bingxiang appointed as a non-executive director of Sinopharm.

According to the process outlined in the "State-controlled Board Resolution" at the end of August, Zhao Bingxiang was elected as the Chairman of the Board. This appointment will only take effect after the shareholders approve his appointment as a non-executive director at the shareholders' meeting. Zhao Bingxiang's appointment as a non-executive director of Sinopharm Group Co., Ltd. also signifies the effectiveness of his role as Chairman.

Eli Lilly China Vice President Resigns

According to "Luo Shi Xiong" news, Fu Qi Yue, Vice President of Lilly China's Biomedicines Division, is about to leave her position, with her last working day on September 30, 2024.

Fosun Pharmaceutical Executive President Resigns

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that, effective from September 13, Mr. Li Shengli will no longer serve as the Executive President of the Company.

Hospital Repayment, Latest Adjustment

On September 13, the Jiangxi Provincial Medical Insurance Bureau released the "Notice on the Direct Settlement of Payments for National Medical Insurance Negotiated Drugs by the Medical Insurance Fund and Pharmaceutical Suppliers (Draft for Soliciting Opinions)." Jiangxi Province will implement direct settlement of payments by the medical insurance fund for the procurement and use of national medical insurance negotiated drugs within the agreement period by designated medical institutions under the medical insurance scheme, establishing a direct settlement revolving fund for nationally negotiated drugs.

Gannex Pharma Enters the Obesity Drug Market

On September 17, Ascletis Pharma announced that its small molecule GLP-1R agonist ASC30 is undergoing two Phase I clinical trials in the United States for once-monthly subcutaneous injection and once-daily oral tablet formulations for the treatment of obesity.